Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Research Report 2024
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
According to Mr Accuracy reports’s new survey, global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is projected to reach US$ 2123.1 million in 2029, increasing from US$ 2368.6 million in 2022, with the CAGR of -1.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Treatment of Chemotherapy-Induced Nausea in Cancer Patients market research.
The chemotherapy-induced nausea and vomiting (CINV) treatment market is driven by the increasing prevalence of cancer and the growing adoption of effective antiemetic therapies. Chemotherapy often causes nausea and vomiting, adversely affecting the quality of life of cancer patients. The rise in cancer incidence and the need for better supportive care contribute to market growth as healthcare providers and patients seek reliable CINV treatments to manage these distressing side effects. Moreover, advancements in antiemetic drug development and the introduction of combination therapies have improved treatment efficacy and patient outcomes. However, the market also faces challenges, including the individual variability in CINV response and the need for tailored treatment approaches. Additionally, addressing the cost of antiemetic drugs and ensuring accessibility to patients can pose obstacles for widespread adoption. To succeed, companies must focus on research and development to offer innovative and patient-centric CINV treatments, collaborate with oncologists to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated antiemetic therapies for cancer patients undergoing chemotherapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Acute CINV
Delayed CINV
Breakthrough CINV
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Treatment of Chemotherapy-Induced Nausea in Cancer Patients report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is projected to reach US$ 2123.1 million in 2029, increasing from US$ 2368.6 million in 2022, with the CAGR of -1.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Treatment of Chemotherapy-Induced Nausea in Cancer Patients market research.
The chemotherapy-induced nausea and vomiting (CINV) treatment market is driven by the increasing prevalence of cancer and the growing adoption of effective antiemetic therapies. Chemotherapy often causes nausea and vomiting, adversely affecting the quality of life of cancer patients. The rise in cancer incidence and the need for better supportive care contribute to market growth as healthcare providers and patients seek reliable CINV treatments to manage these distressing side effects. Moreover, advancements in antiemetic drug development and the introduction of combination therapies have improved treatment efficacy and patient outcomes. However, the market also faces challenges, including the individual variability in CINV response and the need for tailored treatment approaches. Additionally, addressing the cost of antiemetic drugs and ensuring accessibility to patients can pose obstacles for widespread adoption. To succeed, companies must focus on research and development to offer innovative and patient-centric CINV treatments, collaborate with oncologists to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated antiemetic therapies for cancer patients undergoing chemotherapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Treatment of Chemotherapy-Induced Nausea in Cancer Patients report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices